Savvy Trades and Investments

[RNsidersbuying]

NBIO .11 - also has a Phase 1 "cancer treatment" + an ongoing covid in-vitro study awaiting an update + a covid vaccine collaboration...

The Company has performed all necessary U.S. preclinical work and developed successful manufacturing techniques for PTB and is now ready to begin Phase 1 Brain Cancer studies.

The Company's response to COVID-19, indicating that Nascent is awaiting results from in vitro testing prior to the next step in its study of PTB and its use against viruses.

Collaboration with Manhattan BioSolutions Inc. in developing vaccines to be used against viruses around the world. The vaccine program employs a recombinant Bacillus Calmette-Guerin (rBCG), genetically engineered to express selected SARS-CoV-2 proteins. Based on preclinical experience with rBCG candidates for oncology indications and its safe track record as a tuberculosis vaccine, Nascent has the reason to believe that rBCG based vaccine against SARS-CoV-2 may be possible to develop.

Nascent expects to apply for grants based on the outcomes of in vitro studies and confirms that the company has requested a pre-IND meeting with the FDA to accelerate trials for the SARS-CoV-2 indications.

https://finance.yahoo.com/news/nascent-biotechs-ceo-provides-corporate-120000084.html

Trading at less than a $4M cap with an approx. $350K quarterly burn. I know you've been watching what the crazies can do to a stock that mentions anything positive re: covid19...and if they miss on the covid therapeutic in-vitro study and/or the vaccine collaboration resulting in the pps taking a nosedive, NBIO would remain a strong buy as the Phase 1 cancer would still be in play...